Acute myeloid leukemia (AML) is a multi-clonal disease, existing as a milieu of clones with unique but related genotypes as initiating clones acquire subsequent mutations. However, bulk sequencing cannot fully capture AML clonal architecture or the clonal evolution that occurs as patients undergo therapy. To interrogate clonal evolution, we performed simultaneous single-cell molecular profiling and immunophenotyping on 43 samples from 32 NPM1-mutated AML patients at different timepoints in disease progression. Here we show that diagnosis and relapse AML samples display similar clonal architecture patterns, but signaling mutations drive increased clonal complexity, specifically at relapse that correlates with overall survival. We uncovered unique genotype-immunophenotype relationships regardless of disease state, suggesting leukemic lineage trajectories can be hard-wired by the mutations present. Analysis of longitudinal samples from patients on front-line AML therapy identified dynamic clonal and immunophenotypic changes consistent with the genotype-immunophenotype relationships we identified.
Building similarity graph...
Analyzing shared references across papers
Loading...
Morgan Drucker
Darren Lee
M. B. Bowman
Blood
University of Pennsylvania
University of Chicago
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Drucker et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d8955f6c1944d70ce06629 — DOI: https://doi.org/10.1182/blood.2025030772